Your browser doesn't support javascript.
loading
Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma.
Richmond, Craig S; Vallatharasu, Yazhini; Deviley, Jake A; Vos, Cullen R; Parsons, Benjamin M; Kenny, Paraic A.
Afiliação
  • Richmond CS; Kabara Cancer Research Institute, Gundersen Medical Foundation, 1300 Badger Street, La Crosse, WI 54601, USA.
  • Vallatharasu Y; Department of Medical Education, Gundersen Health System, La Crosse, WI 54601, USA.
  • Deviley JA; Department of Oncology, Gundersen Health System, La Crosse, WI 54601, USA.
  • Vos CR; Kabara Cancer Research Institute, Gundersen Medical Foundation, 1300 Badger Street, La Crosse, WI 54601, USA.
  • Parsons BM; Department of Oncology, Gundersen Health System, La Crosse, WI 54601, USA.
  • Kenny PA; Kabara Cancer Research Institute, Gundersen Medical Foundation, 1300 Badger Street, La Crosse, WI 54601, USA; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA. Electronic address: pakenny@gundersenhealth.org.
Exp Mol Pathol ; 110: 104260, 2019 10.
Article em En | MEDLINE | ID: mdl-31082388

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Protocolos de Quimioterapia Combinada Antineoplásica / Microglobulina beta-2 / MAP Quinase Quinase Quinases / Proteínas Proto-Oncogênicas B-raf / MAP Quinase Quinase 2 / Melanoma Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Protocolos de Quimioterapia Combinada Antineoplásica / Microglobulina beta-2 / MAP Quinase Quinase Quinases / Proteínas Proto-Oncogênicas B-raf / MAP Quinase Quinase 2 / Melanoma Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article